BioSpace News Archive

Teva will donate 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month

Mylan N.V. (NASDAQ: MYL) today announced its continued commitment to do its part in support of public health needs amidst the evolving COVID-19 pandemic. The company continues to focus its efforts on protecting our employees, producing critically needed medications, and turning our scientific and operational

The first FDA-cleared artificial intelligence diagnostic system for medical imaging, developed by Qlarity Imaging, a portfolio company of Paragon Biosciences, was selected as a “game-changing” innovation by a panel of global business leaders. [19-March-2020] CHICAGO , March 19, 2020 /PRNewswire/ -- Qlarity Imaging today announced that QuantX, the first –ever

Florida Blue announced that it is making an initial investment of $2 million to address urgent health and safety needs in communities across Florida, the company’s latest response to the COVID-19 public health crisis.

Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced the results from field tests conducted in the 2019 growing season in the United States and Canada.

Amid the stringent travel bans the United States and European Union governments have enacted to slow the spread of COVID-19, there are some critical exceptions that need to be made, in order to save lives.

To serve the public’s health amid the novel coronavirus pandemic, BayCare Health System is postponing elective surgical procedures starting Friday through April 30 at its hospitals and ambulatory surgical centers.

Fred Hutchinson Cancer Research Center remains open and committed to our mission of curing cancer and other diseases. We are collectively focusing on how to ensure our researchers and their respective labs are safe and in the best position to manage COVID-19 related disruptions—particularly those we can’t necessarily predict.

OncoOne today announced the close of a EUR 13 million Series A financing round, marking its industry debut. OncoOne will develop several drug modalities to target oxidized macrophage migration inhibitory factor (oxMIF), an isoform of macrophage migration inhibitory factor (MIF) and an exciting new drug target in solid tumor cancer indications

Sequana Medical NV announces its financial results for the year ended 31 December 2019, and provides a business update and an outlook for the remainder of 2020.